Investment analysts at Deutsche Bank AG initiated coverage on shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) in a note issued to investors on Tuesday. The firm set a “hold” rating and a $30.00 price target on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price target would indicate a potential upside of 10.70% from the stock’s current price.

A number of other research analysts also recently issued reports on VRX. Wells Fargo & Co. reiterated a “sell” rating and set a $19.50 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Mizuho reiterated an “underperform” rating on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Rodman & Renshaw reiterated a “buy” rating and set a $90.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. TD Securities reiterated a “hold” rating and set a $38.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Finally, Susquehanna reiterated a “hold” rating and set a $105.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Sunday, May 29th. Six equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has an average rating of “Hold” and a consensus target price of $55.97.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 1.88% on Tuesday, reaching $26.59. 7,859,589 shares of the company’s stock were exchanged. The firm’s market cap is $9.24 billion. The company has a 50 day moving average price of $27.50 and a 200 day moving average price of $29.38. Valeant Pharmaceuticals International has a one year low of $18.55 and a one year high of $225.54.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/valeant-pharmaceuticals-international-inc-vrx-earns-hold-rating-from-analysts-at-deutsche-bank-ag.html

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.47 billion. Valeant Pharmaceuticals International had a negative net margin of 9.29% and a positive return on equity of 46.59%. The company’s revenue for the quarter was down 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.14 earnings per share. Analysts expect that Valeant Pharmaceuticals International will post $6.54 EPS for the current fiscal year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The stock was bought at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the purchase, the director now owns 20,726 shares in the company, valued at approximately $510,895.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 16.37% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in VRX. Acrospire Investment Management LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter worth approximately $108,000. Tower Research Capital LLC TRC boosted its position in shares of Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares during the last quarter. Cacti Asset Management LLC boosted its position in shares of Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 3,400 shares during the last quarter. AGF Investments Inc. boosted its position in shares of Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 4,857 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $200,000. Institutional investors own 63.60% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.